Stock BNGO BIONANO GENOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Real-time Estimate Cboe BZX
Other stock markets
 11:22:49 2024-06-14 am EDT 		5-day change 1st Jan Change
0.835 USD -1.07% Intraday chart for Bionano Genomics, Inc. -5.01% -56.44%
May. 28 Bionano Genomics Raises $18 Million From Private Debentures Placement MT
May. 24 Bionano Genomics, Inc. announced that it has received $18 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bionano Genomics Raises $18 Million From Private Debentures Placement
Bionano Genomics, Inc. Announces Significant Upgrades to its Suite of Computational Tools for Comprehensive Cancer Analysis
Bionano Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023
Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via? Software for Ogm Data Analysis in Constitution Genetic Disease Research
Bionano Genomics, Inc. Announces Publication of Largest Prospective Prenatal Study Comparing Ogm to Chromosomal Microarray Analysis and Karyotyping
Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bionano Genomics, Inc. Reiterates Revenue Guidance for the Full Year 2023
Bionano Genomics Expects $80 Million in Gross Proceeds From Registered Offering, Private Placement
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BNGO Stock
  4. News Bionano Genomics, Inc.
  5. Other languages